Navigation Links
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that guidelines issued by the Department of Health and Human Services (DHHS) recommend that a co-receptor tropism test, such as Monogram's Trofile(TM) assay, should be performed whenever the use of a CCR5 inhibitor is being considered and might also be considered for patients who exhibit virologic failure on a CCR5 inhibitor.

The Panel on Antiretroviral Guidelines for Adult and Adolescents guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services, January 29, 2008, were developed by a working group of the Office of AIDS Research Advisory Counsel, the National Institutes of Health advisory body on HIV research and treatment policy and initiatives. These guidelines follow the FDA's instructions on Selzentry's label, which call for tropism testing prior to prescribing the drug. Pfizer's Selzentry(TM) (maraviroc) is the first CCR5 inhibitor to receive FDA approval.

"The Office of AIDS Research recommendations and DHHS guidelines underscore the importance of using a clinically validated tropism test to determine whether a patient should be treated with a CCR5 inhibitor," said Monogram Biosciences CEO William Young. "Our Trofile assay is the only test currently available that can provide accurate, reproducible results to guide treatment with this new class of medications."

Monogram's Trofile(TM) assay was used to select patients for participation in the pivotal clinical trials that formed the basis of approval for Selzentry and is being used in every advanced CCR5 inhibitor development program currently underway. In addition to calling
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
3. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
4. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
7. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
8. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
9. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
10. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... PARSIPPANY, N.J., July 7, 2011 Watson Pharmaceuticals, Inc. ... United States Court of Appeals for the Federal Circuit ... Southern District of Florida,s February 2011 decision that Watson,s ... Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed an Abbreviated New Drug Application ... (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. ... of Shire LLC,s Vyvanse®. Vyvanse® is a prescription ...
Cached Medicine Technology:Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit 2Watson Confirms Vyvanse® Patent Challenge 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... University is collaborating on the development of a potential ... An international team of Monash and international researchers ... (MMV) Project of the Year award in recognition of ... drug candidate for clinical testing. Tanzanian President Kikwete ...
... (ALS) could lose brain function earlier than is noticeably ... care. Physicians need a method to assess these sensitive ... neuropsychological tests. Penn State College of Medicine researchers ... deficits in judgment and problem-solving in ALS patients. FTD ...
... HealthDay Reporter , TUESDAY, June 21 (HealthDay News) -- In ... U.S. Food and Drug Administration on Tuesday released nine graphic warning ... later than September 2012. One image shows a man,s ... from a hole in his neck -- the result of a ...
... HOBOKEN, NJ A recent study published in ... Coenzyme Q10 (CoQ10) combination (PycnoQ10) taken by stable heart ... strengthens the heart, increasing the blood volume ejected with ... supply to the organs improves, and patients become more ...
... with prostate cancer and who are also smokers have ... cancer-specific death, according to a study in the June ... had an increased likelihood of prostate cancer recurrence. ... aggressive prostate cancer and prostate cancer mortality. However, studies ...
... Reporter , TUESDAY, June 21 (HealthDay News) -- When arranging ... ask if there are any unlocked guns in the prospective ... with kids contain unlocked, loaded guns, experts say, and dozens ... why the Center to Prevent Youth Violence (PAX) has joined ...
Cached Medicine News:Health News:Major malaria drug research award 2Health News:Brief exam diagnoses cognitive impairment in ALS patients 2Health News:FDA Unveils Graphic Images for Cigarette Packs 2Health News:FDA Unveils Graphic Images for Cigarette Packs 3Health News:FDA Unveils Graphic Images for Cigarette Packs 4Health News:Study shows pine bark naturally improves heart function 2Health News:Study shows pine bark naturally improves heart function 3Health News:Study shows pine bark naturally improves heart function 4Health News:Being a smoker at time of prostate cancer diagnosis linked with increased risk of death 2Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 2Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 3Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 4
... 14A and 14C have been approved. The three ... the variations in the size of the individual ... are designed to stabilize the capsule and have ... of U.S. ophthalmologists. For implatations of the ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Hannum rongeur/grasper with teth in jaws and non-locking design....
Medicine Products: